Group 1 - The company plans to use part of its idle raised funds, not exceeding RMB 700 million, to temporarily supplement working capital for innovative drug research and other related business activities, with a usage period of no more than 12 months [1][4][6] - The total amount raised from the issuance of shares was RMB 3,763,999,989, with a net amount of RMB 3,731,054,180 after deducting issuance costs [1][3][39] - The company has established a special account for the raised funds and signed a tripartite supervision agreement with the sponsor and the bank [2][39] Group 2 - The company intends to use up to RMB 2.6 billion of temporarily idle raised funds for cash management, allowing for rolling use within a 12-month period [11][14][24] - The cash management will focus on purchasing safe, liquid, and principal-protected products, ensuring that the funds are not used for stock trading or other speculative activities [15][19][22] - The company will ensure that cash management does not affect the normal operation and safety of the raised funds [24][25] Group 3 - The company has approved the use of self-raised funds to pay for part of the investment project costs, which will later be replaced with raised funds on an equal basis [38][40][46] - This approach aims to improve operational efficiency and ensure the smooth progress of investment projects without affecting the normal use of raised funds [45][57] - The company will maintain strict records and oversight of the funds used for this purpose to ensure compliance with regulations [43][46] Group 4 - The company has completed the election of its fifth board of directors and appointed senior management personnel, including the general manager and financial director [27][29][30] - The new board members and management team are expected to enhance the company's governance and operational efficiency [28][30][31] - The company has also decided to abolish the supervisory board, transferring its responsibilities to the audit committee of the board [27][30] Group 5 - The company plans to use part of the raised funds to increase capital in its wholly-owned subsidiary for the implementation of the innovative drug research project [50][54][57] - This capital increase will not change the direction of the raised funds or the content of the project [51][56] - The company will ensure that the management of the raised funds complies with relevant regulations and that the funds are used effectively [52][57]
四川百利天恒药业股份有限公司 关于使用部分闲置募集资金暂时补充流动资金的公告